Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vTalphera, Inc. chief executive officer Vincent J. Angotti reported several equity transactions in company stock. On February 12, 2026, he made an open-market purchase of 105,364 shares of common stock at $0.8123 per share, increasing his direct ownership.
That same day, he received a grant of stock options for 594,000 shares, which vest over four years, with one quarter vesting on the one-year anniversary of the grant and the remainder vesting in 36 monthly installments. On February 10 and 14, 2026, a total of 12,738 shares of common stock were surrendered to cover tax withholdings tied to restricted stock unit vesting. After the February 14 tax-withholding disposition, his direct common stock holdings were 577,395 shares, which include a non-reportable acquisition of 10,000 shares through the company’s employee stock purchase plan.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported two insider transactions. He was granted a stock option covering 205,000 shares of common stock at an exercise price of $0.0000 per share. One fourth of this option vests on the one-year anniversary of the February 12, 2026 grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service. On the same date, he also purchased 35,000 shares of common stock in the open market at $0.8123 per share, bringing his direct common stock holdings to 83,178 shares and his option holdings to 205,000 shares.
TALPHERA, INC. Chief Engineering Officer Badri N Dasu reported multiple equity transactions. On February 12, 2026, he purchased 35,000 shares of common stock at
On February 10 and 14, 2026, a total of 3,127 shares of common stock were surrendered in tax-withholding dispositions related to vesting restricted stock units, as noted in the footnote describing shares surrendered to cover required tax withholdings. Following these transactions, Badri N Dasu directly owned 73,884 shares of common stock in one of the reported positions, reflecting his ongoing equity stake in the company.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported multiple equity transactions in company stock. He purchased 45,000 shares of common stock in an open-market transaction at
He was also granted a stock option for 260,000 shares of common stock, with one quarter vesting on the one-year anniversary of the
Talphera, Inc. received an updated ownership filing showing that investor Laurence W. Lytton and the Lytton-Kambara Foundation together report beneficial ownership of 2,730,718 shares of Talphera common stock, or 5.9% of the company.
Both reporting persons have shared voting and shared dispositive power over these shares, with no sole power to vote or dispose. The percentage is based on 46,609,618 shares outstanding as of November 5, 2025, as cited from Talphera’s Form 10-Q. They certify the holdings were not acquired to change or influence control of Talphera.
Rosalind Advisors and affiliates have filed an amended Schedule 13G reporting a sizable passive stake in Talphera, Inc. common shares. Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon report beneficial ownership of 13,150,954 Talphera common shares, representing 9.9% of the class based on 46,609,618 shares outstanding as of November 5, 2025.
The position consists of 3,579,273 common shares plus additional shares issuable from warrants and pre‑funded warrants, some of which are subject to a 9.99% ownership blocker. The reporting persons certify the holdings are in the ordinary course of business and not for the purpose of influencing control.
Talphera, Inc. received an updated ownership disclosure showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together beneficially own 4,661,502 shares of Talphera common stock, representing 9.8% of the outstanding class as of the event date.
The filing notes rights to purchase an additional 5,454,545 common shares in a second closing, but these are not currently exercisable because of beneficial ownership limits. The reporting persons state the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Talphera.
Talphera, Inc. filed a preliminary S-3 prospectus registering the resale by selling stockholders of up to 1,023,890 shares of common stock and up to 1,706,484 shares issuable upon exercise of pre-funded warrants. The company is not selling any securities in this offering.
Talphera will not receive proceeds from sales by the selling stockholders; they will receive all sale proceeds, while Talphera covers registration expenses. The shares may be sold in public or private transactions at market or negotiated prices. The last reported sale price of TLPH was $1.26 on October 27, 2025.
Shares outstanding were 46,609,618 as of October 25, 2025; this is a baseline figure, not the amount being offered.
Talphera, Inc. (TLPH) filed a Form S-8 registering 1,400,000 additional shares of common stock for its Amended and Restated 2020 Equity Incentive Plan and 100,000 additional shares for its Amended and Restated 2011 Employee Stock Purchase Plan. The filing uses General Instruction E to incorporate prior S‑8 registrations by reference, streamlining the addition to the company’s existing employee equity programs.
The registration relates to shares issuable under established compensation plans and includes standard exhibits and consents. The filing was signed by Chief Executive Officer Vincent J. Angotti, with the company’s CFO designated as agent for service.
Talphera (TLPH) disclosed a director equity grant on Form 4. On 10/23/2025, the reporting person received 4,267 restricted stock units, each representing one share of common stock. The RSUs vest 100% on the first anniversary of the grant date, contingent on continuous service.
On the same date, the director was granted a stock option for 25,600 shares at an exercise price of $1.14, expiring on 10/22/2035, with 100% vesting after one year. Following these transactions, the director beneficially owned 8,859 common shares, held directly.